DNB Asset Management AS Buys 166 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

DNB Asset Management AS boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.6% during the 2nd quarter, HoldingsChannel reports. The firm owned 27,463 shares of the biopharmaceutical company’s stock after buying an additional 166 shares during the period. DNB Asset Management AS’s holdings in Alnylam Pharmaceuticals were worth $8,955,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Atlantic Union Bankshares Corp bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth $30,000. SVB Wealth LLC purchased a new stake in Alnylam Pharmaceuticals in the first quarter worth about $27,000. Ameritas Advisory Services LLC purchased a new stake in Alnylam Pharmaceuticals in the second quarter worth about $42,000. AlphaQuest LLC bought a new position in Alnylam Pharmaceuticals during the 2nd quarter worth about $43,000. Finally, Parkside Financial Bank & Trust increased its position in Alnylam Pharmaceuticals by 32.6% during the 2nd quarter. Parkside Financial Bank & Trust now owns 179 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 44 shares during the period. 92.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ALNY. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 10th. Bank of America upped their target price on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. HC Wainwright set a $570.00 target price on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, November 4th. Evercore ISI boosted their price target on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research report on Thursday, September 11th. Finally, Piper Sandler restated an “overweight” rating and set a $489.00 price objective (up from $449.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. Twenty-three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $482.17.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 10,000 shares of the stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $451.27, for a total value of $4,512,700.00. Following the completion of the transaction, the chief executive officer directly owned 65,409 shares of the company’s stock, valued at $29,517,119.43. This trade represents a 13.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Pushkal Garg sold 3,022 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the completion of the sale, the executive vice president owned 20,221 shares of the company’s stock, valued at $9,129,377.08. This trade represents a 13.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 78,328 shares of company stock valued at $35,705,793 in the last 90 days. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $436.38 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The stock has a fifty day moving average price of $457.30 and a 200-day moving average price of $390.58. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The firm has a market cap of $57.65 billion, a PE ratio of -176.67 and a beta of 0.30.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.